ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Search Videos by Topic or Participant
Browse by Series:

Immunotherapy in Non-Small Cell Lung Cancer

Panelists: Roy S. Herbst, MD, PhD, Yale; Mark A. Socinski, MD, University of Pittsburgh;Thomas E. Stinchcombe, MD, UNC; Anne S. Tsao, MD, MD Ande
Published: Friday, Mar 27, 2015
For High-Definition, Click
Foundational research into the underlying mechanisms related to tumor-induced immune suppression on infiltrating lymphocytes and immune cells in the tumor microenvironment has led to therapeutic advances, such as PD-1 inhibition, explains Mark A. Socinski, MD. PD-1 is expressed on immune cells and interacts with PD-L1 and PD-L2 on normal cells. Overexpression of PD-L1 causes the downregulation of PD-1 expressing cells, which is a mechanism hijacked by tumors to avoid the immune system. 

The development of a way to combat the downregulation of the immune system through the PD-1 pathway makes sense, Socinski notes. Currently, several antibodies are being developed in the non-small cell lung cancer (NSCLC) setting. On March 4, 2015, the FDA approved the PD-1 inhibitor nivolumab as a treatment for patients with advanced squamous NSCLC who have progressed on or after platinum-based chemotherapy.

Both PD-1 and PD-L1 blocking agents induce a consistent response rate ranging from 15% to 25%, Socinski notes. One of the remarkable things about the response seen with PD-1 inhibition is the durability. The new goal for research is to gain a better understand of the toxicities resulting from these agents, which are very different from standard cytotoxic chemotherapies or the TKI class of drugs. These agents can produce immune-related toxicities that need to be understood. 

There is a clear role for immunotherapeutics in lung cancer, Socinski states. Several phase I and II trials are looking at combining these immune checkpoint inhibitors, such as the PD-1 compounds with the anti-CTLA4 agents to further enhance responses. PD-1 and CTLA-4 combinations have demonstrated promise as treatments for patients with melanoma, suggesting they will also be effective in NSCLC.
Slider Left
Slider Right
For High-Definition, Click
Foundational research into the underlying mechanisms related to tumor-induced immune suppression on infiltrating lymphocytes and immune cells in the tumor microenvironment has led to therapeutic advances, such as PD-1 inhibition, explains Mark A. Socinski, MD. PD-1 is expressed on immune cells and interacts with PD-L1 and PD-L2 on normal cells. Overexpression of PD-L1 causes the downregulation of PD-1 expressing cells, which is a mechanism hijacked by tumors to avoid the immune system. 

The development of a way to combat the downregulation of the immune system through the PD-1 pathway makes sense, Socinski notes. Currently, several antibodies are being developed in the non-small cell lung cancer (NSCLC) setting. On March 4, 2015, the FDA approved the PD-1 inhibitor nivolumab as a treatment for patients with advanced squamous NSCLC who have progressed on or after platinum-based chemotherapy.

Both PD-1 and PD-L1 blocking agents induce a consistent response rate ranging from 15% to 25%, Socinski notes. One of the remarkable things about the response seen with PD-1 inhibition is the durability. The new goal for research is to gain a better understand of the toxicities resulting from these agents, which are very different from standard cytotoxic chemotherapies or the TKI class of drugs. These agents can produce immune-related toxicities that need to be understood. 

There is a clear role for immunotherapeutics in lung cancer, Socinski states. Several phase I and II trials are looking at combining these immune checkpoint inhibitors, such as the PD-1 compounds with the anti-CTLA4 agents to further enhance responses. PD-1 and CTLA-4 combinations have demonstrated promise as treatments for patients with melanoma, suggesting they will also be effective in NSCLC.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x